Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in HIV-infected patients with low CD4+ counts
NCT03367754Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Pembrolizumab with Placebo (2 arms). Primary endpoint: Number of Participants With Either Grade 2 or Higher Autoimmune Events and Grade 3 or Higher Adverse Events at 48 weeks. Started Aug 2018; status: terminated.
02
Drugs
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03367754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367754.